{Also includes Quality: moderate CRC = 18 refusal Nanjing, China) recurrence the aim of this study; it pop 1 data} provided some data so Gynaecologic = 13 Tumour accessible via 2450 MHz, 1–100 W Statistical analyses has been included on percutaneous approach Breast = 10 Cool-shaft antenna None undertaken that basis ≤3 hepatic lesions with max Gastric = 9 Max 3 sessions Duration of follow-up diameter of 4 cm Lung = 8 Total treatment time Not reported separately for pop 2; Absence or portal vein thrombosis s for 2 groups compared in the Prostate = 2 or extrahepatic metastases study (close to and further from Oesophageal = 1 Prothrombin time of <25 s diaphragm), follow-up was 11.5 ± Male/female: not 10.3 months and 12.7 ± 9.6 Prothrombin activity >40% reported by cancer months, respectively Platelet count >40 cells × 109/L type Exclusion Age: not reported by cancer type New lesions found after previous MTA, TACE, RFA or other therapy Also received immunotherapy Lost to follow-up Objectives To compare patients undergoing MTA at sites close to and further away from the diaphragm. Some data are provided for outcomes relevant to pop 2 Alexander et al Case series N = 39 Inclusion MTA Outcomes Some patients also had () resection, but numbers Level IV Metastases from: Single liver neoplasm Percutaneous or Survival not reported USA intraoperative Quality: moderate CRC = 27 Refused or not suitable for resection Statistical analyses {Also includes Five different machines Breast = 4 Exclusion Kaplan–Meier analysis pop 1 data} used: either 915 MHz Carcinoid = 2 Radiographic evidence of nodal Duration of follow-up: (Evident, Covidien, USA’ disease Lung = 2 Not reported, but results provided MicroThermX, BSD Medical, Adenopathy for survival at 1 year Melanoma = 2 USA; AveCure, MedWaves, Extrahepatic disease CCA = 1 USA) or 2450 MHz (Certus International normalised ratio of 140, NeuWave, USA; Anal = 1 >1.8 on day of ablation Amica, Hospital Service, Mean age ± SD:
{Also includes pop 1 data} Quality: moderate CRC = 18 Gynaecologic = 13 Breast = 10 Gastric = 9 Lung = 8 Prostate = 2 Oesophageal = 1 Male/female: not reported by cancer type Age: not reported by cancer type refusal Tumour accessible via percutaneous approach ≤3 hepatic lesions with max diameter of 4 cm Absence or portal vein thrombosis or extrahepatic metastases Prothrombin time of <25 s Prothrombin activity >40% Platelet count >40 cells × 109/L Exclusion New lesions found after previous MTA, TACE, RFA or other therapy Also received immunotherapy Lost to follow-up Objectives To compare patients undergoing MTA at sites close to and further away from the diaphragm. Some data are provided for outcomes relevant to pop 2 Nanjing, China) 2450 MHz, 1–100 W Cool-shaft antenna Max 3 sessions Total treatment time s recurrence Statistical analyses None undertaken Duration of follow-up Not reported separately for pop 2; for 2 groups compared in the study (close to and further from diaphragm), follow-up was 11.5 ± 10.3 months and 12.7 ± 9.6 months, respectively the aim of this study; it provided some data so has been included on that basis Alexander et al () USA {Also includes pop 1 data} Case series Level IV Quality: moderate N = 39 Metastases from: CRC = 27 Breast = 4 Carcinoid = 2 Lung = 2 Melanoma = 2 CCA = 1 Anal = 1 Mean age ± SD: Inclusion Single liver neoplasm Refused or not suitable for resection Exclusion Radiographic evidence of nodal disease Adenopathy Extrahepatic disease International normalised ratio of >1.8 on day of ablation MTA Percutaneous or intraoperative Five different machines used: either 915 MHz (Evident, Covidien, USA’ MicroThermX, BSD Medical, USA; AveCure, MedWaves, USA) or 2450 MHz (Certus 140, NeuWave, USA; Amica, Hospital Service, Outcomes Survival Statistical analyses Kaplan–Meier analysis Duration of follow-up: Not reported, but results provided for survival at 1 year Some patients also had resection, but numbers not reported
1402-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx